Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

7 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Efficacy and safety of tezepelumab versus placebo in adults with moderate to very severe chronic obstructive pulmonary disease (COURSE): a randomised, placebo-controlled, phase 2a trial.
Singh D, Brightling CE, Rabe KF, Han MK, Christenson SA, Drummond MB, Papi A, Pavord ID, Molfino NA, Almqvist G, Kotalik A, Hellqvist Å, Gołąbek M, Sindhwani NS, Ponnarambil SS; COURSE study investigators. Singh D, et al. Among authors: kotalik a. Lancet Respir Med. 2024 Dec 6:S2213-2600(24)00324-2. doi: 10.1016/S2213-2600(24)00324-2. Online ahead of print. Lancet Respir Med. 2024. PMID: 39653044
Oral and inhaled corticosteroid dose reductions with tezepelumab versus placebo in patients with severe, uncontrolled asthma from DESTINATION.
Wechsler ME, Stolz D, Lugogo NL, Caveney S, Almqvist G, Bednarczyk A, Kotalik A, Chandarana S, Ambrose CS. Wechsler ME, et al. Among authors: kotalik a. J Allergy Clin Immunol Pract. 2024 Nov;12(11):3128-3131.e2. doi: 10.1016/j.jaip.2024.08.008. Epub 2024 Aug 8. J Allergy Clin Immunol Pract. 2024. PMID: 39127103 Free article. No abstract available.
Biomarkers and clinical outcomes after tezepelumab cessation: Extended follow-up from the 2-year DESTINATION study.
Brightling CE, Caminati M, Llanos JP, Caveney S, Kotalik A, Griffiths JM, Lundahl A, Israel E, Pavord ID, Wechsler ME, Porsbjerg C, Corren J, Gołąbek M, Martin N, Ponnarambil S. Brightling CE, et al. Among authors: kotalik a. Ann Allergy Asthma Immunol. 2024 Sep;133(3):310-317.e4. doi: 10.1016/j.anai.2024.04.031. Epub 2024 Apr 30. Ann Allergy Asthma Immunol. 2024. PMID: 38697286 Free article. Clinical Trial.